/SKYE
SKYE Stock - Skye Bioscience, Inc.
Healthcare|BiotechnologyNASDAQ
$0.93-6.99%
$0.07 (-6.99%) • Dec 19
48
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.13
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+115.1%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SKYE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.92 – $0.94
TARGET (TP)$2.00
STOP LOSS$0.86
RISK/REWARD1:15.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.68
52W High$5.75
52W Low$0.93
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-1,872 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-30,192,718 | $-34,735,173 | $-18,311,732 | $-7,847,714 | $-6,289,013 |
| Net Income | $-26,567,123 | $-37,644,784 | $-19,481,602 | $-8,522,182 | $-6,561,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.73 | $-5.37 | $-8.77 | $-5.00 | $-7.11 |
Company Overview
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
75%
Hold / Neutral
2
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish2 Neutral/Bearish
Price Targets
$14
Average Target
↑ 1393.4% Upside
Now
$2
Low
$14
Average
$25
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 6th 2025 | Craig Hallum | Downgrade | Hold | $2 |
| October 6th 2025 | Cantor Fitzgerald | Downgrade | Neutral | $2 |
| August 15th 2025 | Evercore ISI | Initiation | Outperform | $10 |
| February 28th 2025 | William Blair | Initiation | Outperform | - |
| September 30th 2024 | Scotiabank | Initiation | Sector Outperform | $20 |
| September 10th 2024 | JMP Securities | Initiation | Mkt Outperform | $15 |
| July 9th 2024 | Craig Hallum | Initiation | Buy | $18 |
| May 23rd 2024 | Cantor Fitzgerald | Initiation | Overweight | $21 |
| April 12th 2024 | Oppenheimer | Initiation | Outperform | $25 |
| February 5th 2024 | Piper Sandler | Initiation | Overweight | $12 |
Earnings History & Surprises
SKYEBeat Rate
50%
Last 8 quarters
Avg Surprise
-8.2%
EPS vs Estimate
Beats / Misses
4/3
1 met exactly
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
-65.8%
$-0.63vs$-0.38
Q2 24
-12.5%
$-0.18vs$-0.16
Q3 24
0.0%
$-0.20vs$-0.20
Q4 24
+15.4%
$-0.22vs$-0.26
Q1 25
+14.3%
$-0.24vs$-0.28
Q2 25
+9.7%
$-0.28vs$-0.31
Q3 25
-29.4%
$-0.44vs$-0.34
Q4 25
+3.0%
$-0.32vs$-0.33
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.29 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.33 | $-0.32 | +3.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.34 | $-0.44 | -29.4% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.26 | $-0.22 | +15.4% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.20 | $-0.20 | 0.0% | = MET |
Q2 2024 | May 10, 2024 | $-0.16 | $-0.18 | -12.5% | ✗ MISS |
Q1 2024 | Mar 22, 2024 | $-0.38 | $-0.63 | -65.8% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | — | $-3.17 | — | — |
Q3 2023 | Aug 7, 2023 | — | $-0.80 | — | — |
Q2 2023 | May 11, 2023 | — | $-2.50 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-5.00 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-2.50 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-2.50 | — | — |
Q2 2022 | May 6, 2022 | — | $-2.50 | — | — |
Q1 2022 | Mar 25, 2022 | — | $-1.52 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-1.10 | — | — |
Q3 2021 | Aug 6, 2021 | — | $-2.50 | — | — |
Latest News
Skye Bioscience In Presentation, Reports Nimacimab Shows ~3% Additional Weight Loss Over Semaglutide Alone at 26 Weeks With Continued Separation, Positioned as Scalable Add-On to Enhance Incretin Therapy
📈 PositiveBenzinga•Nov 24, 2025, 12:10 PM
Skye Bioscience Q3 EPS $(0.32) Misses $(0.31) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 09:05 PM
Skye Bioscience To Highlight Recent Topline Data From CBeyond, Phase 2 Proof-Of-Concept Study Of Nimacimab, Skye's Peripherally-Restricted CB1 Inhibitor Antibody, At ObesityWeek 2025
➖ NeutralBenzinga•Nov 5, 2025, 12:28 PM
Skye Bioscience shares are trading lower after the company announced the nimacimab monotherapy arm did not meet primary endpoint in CBeyond study.
📉 NegativeBenzinga•Oct 6, 2025, 02:23 PM•Also:
Skye plummets 60% on mid-stage data for nimacimab for weight loss
📉 NegativeSeeking Alpha•Oct 6, 2025, 01:30 PM•Also:
Skye Bioscience Released Topline Data From Its 26-week Phase 2a CBeyond Proof-of-concept Study Of Nimacimab, The Nimacimab Monotherapy Arm Did Not Achieve The Primary Endpoint Of Weight Loss Compared To Placebo
📉 NegativeBenzinga•Oct 6, 2025, 11:07 AM
HC Wainwright & Co. Initiates Coverage On Skye Bioscience with Buy Rating, Announces Price Target of $20
📈 PositiveBenzinga•Sep 30, 2025, 11:22 AM
Skye Presents Phase 1b Data Showing Nimacimab Safe And Well Tolerated In MASLD Patients At EASD Annual Meeting
📈 PositiveBenzinga•Sep 19, 2025, 11:04 AM
Skye's Nimacimab Boosts Tirzepatide Results And Helps Maintain Weight Loss In Mouse Studies
📈 PositiveBenzinga•Sep 4, 2025, 11:10 AM
Skye Bioscience Announces Completion Of 26-Week Treatment Phase In Phase 2a CBeyond Trial Evaluating Nimacimab For Obesity
➖ NeutralBenzinga•Sep 2, 2025, 11:03 AM
Frequently Asked Questions about SKYE
What is SKYE's current stock price?
Skye Bioscience, Inc. (SKYE) is currently trading at $0.93 per share. The stock has moved -6.99% today.
What is the analyst price target for SKYE?
The average analyst price target for SKYE is $2.00, based on 1 analyst.
What sector is Skye Bioscience, Inc. in?
Skye Bioscience, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SKYE's market cap?
Skye Bioscience, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does SKYE pay dividends?
No, Skye Bioscience, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to SKYE for comparison